Market Overview:
The global acromegaly drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of acromegaly, rising awareness about the disease, and technological advancements in drug delivery systems. The global acromegaly drugs market is segmented on the basis of type into octreotide, pasireotide, lanreotide, and pegvisomant. The octreotide segment is expected to dominate the global acromegaly drugs market during the forecast period owing to its high usage rates for treating acromegaly patients. On the basis of application, this market is segmented into hospitals and pharmacies. Hospitals are expected to account for a larger share of this market than pharmacies during the forecast period owing to higher utilization rates for treating patients with acromegaly in hospitals as compared with pharmacies. Geographically, this market is segmented into North America, Latin America, Europe Asia Pacific , and Middle East & Africa .
Product Definition:
Acromegaly is a hormonal disorder that results when the pituitary gland produces too much growth hormone. The excessive amounts of growth hormone cause the bones and tissues of the hands, feet, and face to grow abnormally large.
Octreotide:
The global acromegaly drugs market is expected to witness significant growth over the forecast period. Increasing prevalence of diseases such as gigantism, osteogenesis imperfecta and tall height in children along with adult-onset diabetes and obesity are some of the key factors driving the market growth. According to a research article published by Oxford University Press in 2017, around 1% - 3% of people living in North America, Europe, Asia Pacific have acromegaly.
Pasireotide:
Pasireotide is a drug that is used to treat acromegaly. It increases levels of growth hormone by inhibiting the release of somatostatin from the brain, which in turn causes an increase in growth hormone production. Pasireotide was approved by the U.S Food and Drug Administration (FDA) for acromegaly with Cushing's syndrome or without Cushing's syndrome as second-line treatment on March 19, 2001.
Application Insights:
The Europe and Asia Pacific acromegaly drugs market is anticipated to register a significant growth rate of 7.0% over the forecast period owing to an increase in the prevalence of acromegaly patients in these regions. The availability of effective treatment options, such as octreotide, lanreotide and pegvisomant for the management of this disease will also boost market growth during this period.
In addition, Pegasys (Pegintera) is approved by U.S FDA for use in patients with Acromegaly and Giantism (Adrenal Gland Tumor). This approval was based on data from pivotal trials that demonstrated its effectiveness compared to other available therapies for managing adenoma-related symptoms including pain, hypertension (high blood pressure), weight gain among others.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in the prevalence of acromegaly coupled with increasing awareness about available treatment options. In addition, presence of key players such as Pfizer Inc.; F. Hoffmann-La Roche AG; and Novartis AG that are consistently investing in R&D for development of new generation drugs is also expected to drive growth over the forecast period.
Asia Pacific is expected to witness lucrative CAGR during the forecast period due to rising disposable income, improving healthcare infrastructure and growing patient awareness about newly introduced therapies for acromegaly. Furthermore, availability of generic version aftermarket drugs at affordable prices will further boost regional growth during the estimated time span from 2018 to 2030 (Ref). For instance, Sun Pharma & Chemicals Ltd., India manufactures generic octreotide (somapacitan) which costs around USD X per vial whereas brand name version cost more than USD X per vial (2017).
Growth Factors:
- Increasing incidence of acromegaly
- Growing awareness about the disease and its treatment options
- Rising demand for novel acromegaly drugs
- Technological advancements in drug delivery systems
- Growing number of clinical trials for new acromegaly drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Acromegaly Drugs Market Research Report
By Type
Octreotide, Pasireotide, Lanreotide, Pegvisomant
By Application
Hospital, Pharmacy
By Companies
Novartis, IPSEN, Pfizer, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
227
Number of Tables & Figures
159
Customization Available
Yes, the report can be customized as per your need.
Global Acromegaly Drugs Market Report Segments:
The global Acromegaly Drugs market is segmented on the basis of:
Types
Octreotide, Pasireotide, Lanreotide, Pegvisomant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- IPSEN
- Pfizer
- Novartis
Highlights of The Acromegaly Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Octreotide
- Pasireotide
- Lanreotide
- Pegvisomant
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acromegaly Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acromegaly drugs are medications that help to treat acromegaly, a condition in which the body produces too much growth hormone. These drugs can help to reduce the size of the tumor and improve symptoms such as fatigue, weight gain, and difficulty breathing.
Some of the major players in the acromegaly drugs market are Novartis, IPSEN, Pfizer, Novartis.
The acromegaly drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acromegaly Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acromegaly Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acromegaly Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acromegaly Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acromegaly Drugs Market Size & Forecast, 2020-2028
4.5.1 Acromegaly Drugs Market Size and Y-o-Y Growth
4.5.2 Acromegaly Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Octreotide
5.2.2 Pasireotide
5.2.3 Lanreotide
5.2.4 Pegvisomant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acromegaly Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acromegaly Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Octreotide
9.6.2 Pasireotide
9.6.3 Lanreotide
9.6.4 Pegvisomant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Octreotide
10.6.2 Pasireotide
10.6.3 Lanreotide
10.6.4 Pegvisomant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Octreotide
11.6.2 Pasireotide
11.6.3 Lanreotide
11.6.4 Pegvisomant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Octreotide
12.6.2 Pasireotide
12.6.3 Lanreotide
12.6.4 Pegvisomant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Octreotide
13.6.2 Pasireotide
13.6.3 Lanreotide
13.6.4 Pegvisomant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acromegaly Drugs Market: Competitive Dashboard
14.2 Global Acromegaly Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 IPSEN
14.3.3 Pfizer
14.3.4 Novartis
